Pfizer to Acquire InnoPharma, Inc. | Pfizer Pharmaceutical News and Me...
`
`http://press.pfizer.com/press-release/pfizer-acquire-innopharma-inc
`
`Health Care Professionals
`
`Partnering
`
`Careers
`
`Contact Us
`
`Search Pfizer.com
`
`Home News & Media Press Releases Pfizer to Acquire InnoPharma, Inc.
`
`News & Media
`
`Press
`Releases
`Press
`Release
`Archive
`Press
`Statements
`Archive
`
`Featured
`Stories
`
`Video Gallery
`
`Frequently
`Requested
`Info
`
`Press Kits
`
`Download
`Multimedia
`
`Social Media
`
`Contact Pfizer
`Media
`Relations
`
`Pfizer to Acquire InnoPharma, Inc.
`InnoPharma Has Established Track Record in the Development of Hard-to-Make, Differentiated, Sterile Injectable Products
`
`Portfolio of 10 Approved Products and Pipeline of More Than 30 Products in Development; 19 Pending Approval with the
`United States Food and Drug Administration
`
`Wednesday, July 16, 2014 9 26 am EDT
`Dateline
`NEW YORK and PISCATAWAY, N.J.
`
`Public Company Information
`NYSE: PFE
`US7170811035
`
`NEW YORK and PISCATAWAY, N.J.--(BUSINESS WIRE)--
`Pfizer Inc. (NYSE:PFE) and InnoPharma, Inc., a privately held pharmaceutical development
`company, today announced that they have entered into an agreement under which Pfizer will
`acquire InnoPharma.
`
`Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of
`$225 million, with up to $135 million of contingent milestone payments.
`
`InnoPharma’s current portfolio includes 10 generic products approved by the United States (U.S.)
`Food and Drug Administration (FDA). The company also has a pipeline of 19 products filed with
`FDA and more than 30 injectable and ophthalmic products under development. The company seeks
`to develop novel formulations of existing drugs, including hard-to-make products, such as those that
`require complex manufacturing capabilities or have bio-equivalency challenges, in areas such as
`cancer and central nervous disorders.
`
`"InnoPharma’s technical
`capabilities in bringing
`complex generics to market,
`coupled with its strong
`talent and product pipeline,
`build on our efforts to
`develop and commercialize
`critically important
`medicines for the patients
`who need them."
`
`“Today’s announcement is an important milestone as we continue to look for innovative growth opportunities for our sterile injectables
`portfolio, which will increase to seventy three products with this acquisition,” said John Young, group president, Pfizer Global
`Established Pharma (GEP). “InnoPharma’s technical capabilities in bringing complex generics to market, coupled with its strong talent
`and product pipeline, build on our efforts to develop and commercialize critically important medicines for the patients who need them.”
`
`Pfizer Injectables is part of the Global Established Pharma business and includes the manufacturing, production and sale of human
`pharmaceutical and surgiceutical products. The current active sterile injectable portfolio consists of 44 products with over 190
`presentations in the U.S. The new Pfizer portfolio of seventy three products will include currently marketed, as well as products filed
`with the FDA.
`
`Established in 2005, InnoPharma has a comprehensive research and development facility in Piscataway, NJ. The company has
`developed capabilities in complex injectable delivery forms, including pens and depot injectibles, and is working to leverage this
`expertise to expand into new dosage forms, including oral suspensions and nasals.
`
`“InnoPharma has emerged as a strong development company over the years, with a portfolio of complex and differentiated products
`that provide value and options to patients and payors, and has an excellent team that has executed on this business model so
`successfully,” said Navneet Puri, PhD, President and CEO of InnoPharma. “We are very pleased to continue to provide this value as
`part of Pfizer, which has demonstrated its leadership within the pharmaceutical industry and a focus on improving patient health.”
`
`The closing of the transaction is subject to U.S. regulatory approval and is expected to occur during the third quarter.
`
`Pfizer’s legal advisor for the transaction was Kaye Scholer LLP. J.P. Morgan served as InnoPharma’s financial advisor, while Morgan,
`Lewis & Bockius LLP served as its legal advisor.
`
`Pfizer Inc. Working together for a healthier world
`®
`
`At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We
`strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our
`global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day,
`Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge
`
`1 of 3
`
`4/8/2015 1:28 PM
`
`SENJU EXHIBIT 2216
`INNOPHARMA v SENJU
`IPR2015-00903
`
`PAGE 1 OF 3
`
`

`
`Pfizer to Acquire InnoPharma, Inc. | Pfizer Pharmaceutical News and Me...
`
`http://press.pfizer.com/press-release/pfizer-acquire-innopharma-inc
`
`the most feared diseases of our time. Consistent wi h our responsibility as one of the world's premier innovative biopharmaceutical
`companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable,
`affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To
`learn more, please visit us at www.pfizer.com.
`
`About InnoPharma, Inc.
`
`InnoPharma is a sterile product development company, focused on developing complex generic and innovative specialty
`pharmaceutical products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under
`development, with formulations including solutions, suspension, lyophilized, emulsions, liposomes, micelles and lipid complexes.
`InnoPharma’s pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize
`polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of
`the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at
`www.innopharmainc.com.
`
`PFIZER DISCLOSURE NOTICE
`
`The information contained in this release is as of July 16, 2014. Pfizer assumes no obligation to update forward-looking statements
`contained in this release as the result of new information or future events or developments.
`
`This release contains forward-looking information about an agreement by Pfizer to acquire InnoPharma, and about InnoPharma’s
`development pipeline and its technology platforms, including their potential benefits, that involves substantial risks and uncertainties.
`Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement in the anticipated
`timeframe or at all; the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and
`when to approve any applications for InnoPharma’s product candidates, as well as their decisions regarding labeling and other matters
`that could affect their availability or commercial potential; and competitive developments.
`
`A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
`31, 2013 and in its subsequent reports on Form 10-Q and Form 8-K.
`
`Photos/Multimedia Gallery Available: http://www.businesswire.com/mul imedia/home/20140716005762/en/
`
`Multimedia Files:
`Download All Files
`
`Download:
`Download Thumbnail (1.39 KB)
`Download Preview (3.48 KB)
`Download Small (19.64 KB)
`Download Full Size (228.97 KB)
`Download Square (3.68 KB)
`
`Download:
`Download Thumbnail (6.28 KB)
`Download Preview (8 55 KB)
`Download Small (20.41 KB)
`Download Full Size (54.59 KB)
`Download Square (6.63 KB)
`
`Contact:
`Pfizer Media:
`Joan Campion
`+1.212.733 2798 (O)
`+1.201.761 9384 (M)
`Joan.Campion@pfizer.com
`Pfizer Investor:
`Ryan Crowe
`+1.212.733 8160 (O)
`+1.215.260 0914 (M)
`Ryan.Crowe@pfizer.com
`or
`InnoPharma:
`John Deighan, CFO
`+1.732.885 2939
`jdeighan@innopharmainc.com
`
`Contact Us
`Careers
`Global Network
`
`Investors
`Business to Business
`Health Care Professionals
`
`Sitemap
`Terms of Use
`Privacy Policy
`
`Copyright © 2002–2015 Pfizer Inc. All rights reserved. This information is intended only for
`residents of the United States. The product information provided in this site is intended only
`for residents of the United States. The products discussed herein may have different product
`labeling in different countries. Pfizer Inc. is a pharmaceutical company committed to helping
`people improve their health by discovering and developing medicines.
`
`2 of 3
`
`4/8/2015 1:28 PM
`
`PAGE 2 OF 3
`
`

`
`Pfizer to Acquire InnoPharma, Inc. | Pfizer Pharmaceutical News and Me...
`
`http://press.pfizer.com/press-release/pfizer-acquire-innopharma-inc
`
`Business Wire NewsHQ℠
`
`3 of 3
`
`4/8/2015 1:28 PM
`
`PAGE 3 OF 3